Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT05634057

Effectiveness of Anisodamine Hydrobromide Combined With Heparin for the Treatment of Critically Ill Patients With Septic Shock

Conditions: Septic Shock

Sex: All
Ages: 18 Years – 80 Years
Phase: NA
Enrollment: 384
Sponsor: Chen Ying

Summary

The study aimed to investigate the effectiveness of anisodamine hydrobromide combined with heparin in the treatment of septic shock, in the hope that the therapy will provide alternatives to the treatment of septic shock.

Eligibility Criteria

Inclusion Criteria:Patients with septic shockExclusion Criteria:The age of <18 years or >80 years;Patients who were expected to die within 24h before enrollment;Patients who died or withdrew from the experiment due to serious diseases of heart, liver, kidney and other organs or mental diseases before reaching the end of the intervention effect;Patients had received treatment related to septic shock before enrollment, which may affect the observers of effect indicators;patients contraindicated with heparin and anisodamine;Refuse to sign the informed consent;Patients with thrombotic diseases requiring low molecular weight heparin treatment.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05634057). StuddyBuddy aggregates publicly available trial information.